Phase 3Completed

Effect of Duolac 7S Administration on Improving Symptom in Irritable Bowel Syndrome

Sponsor
Cell Biotech Co., Ltd. (Industry)
Enrollment
60 enrolled
Conditions
Irritable Bowel Syndrome
Interventions
Duolac7S; starch
Ages
adults, older adults
Registry
NCT01088971

Full record on ClinicalTrials.gov

From the registry

Gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS). The purpose of this study is to investigate the efficacy of Duolac7S in changing the colonic microflora and improve the symptoms in IBS sufferers. In all, 64 patients with Rome III positive diarrhea type IBS will complete a 6-week multiple centre controlled clinical trial. Patients will be randomized to receive either 2 capsules/day Duolac7S or 2 capsules/day placebo. IBS symptoms will be monitored and scored according to Likert scale. Changes in faecal microflora, stool frequency and form, quality of life (QOL) scores will be also monitored.

Primary outcomes

  • The improvement of IBS symptoms

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started